# STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma

> **NCT00252824** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1000 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy

## Key facts

- **NCT ID:** NCT00252824
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00252824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00252824, "STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00252824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*